UY26131A1 - PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID. - Google Patents

PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID.

Info

Publication number
UY26131A1
UY26131A1 UY26131A UY26131A UY26131A1 UY 26131 A1 UY26131 A1 UY 26131A1 UY 26131 A UY26131 A UY 26131A UY 26131 A UY26131 A UY 26131A UY 26131 A1 UY26131 A1 UY 26131A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
form containing
unitary form
containing clopidogrel
hydrogenosulphate
Prior art date
Application number
UY26131A
Other languages
Spanish (es)
Inventor
Bernard Abramovici Y Lheritier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of UY26131A1 publication Critical patent/UY26131A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La presente invención se refiere a una composición farmacéutica que se presenta en una forma galénica unitaria que contiene una asociación de principios activos de actividad antiagregante plaquetario constituida por ácido acetilsalicílico e hidrogenosulfato de clopidogrel.The present invention refers to a pharmaceutical composition that is presented in a unitary galenic form that contains an association of active principles of antiplatelet activity consisting of acetylsalicylic acid and clopidogrel hydrogensulfate.

UY26131A 1999-04-30 2000-04-28 PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID. UY26131A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905497A FR2792836B3 (en) 1999-04-30 1999-04-30 PHARMACEUTICAL COMPOSITION IN UNIT FORM CONTAINING ASPIRIN AND CLOPIDOGREL HYDROGENOSULFATE

Publications (1)

Publication Number Publication Date
UY26131A1 true UY26131A1 (en) 2000-12-29

Family

ID=9545071

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26131A UY26131A1 (en) 1999-04-30 2000-04-28 PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID.

Country Status (24)

Country Link
EP (1) EP1178809A1 (en)
JP (1) JP2002543137A (en)
KR (1) KR20020005735A (en)
CN (1) CN1359294A (en)
AR (1) AR023789A1 (en)
AU (1) AU4303600A (en)
BR (1) BR0010194A (en)
CA (1) CA2371231A1 (en)
CZ (1) CZ20013887A3 (en)
EA (1) EA200100959A1 (en)
EE (1) EE200100559A (en)
FR (1) FR2792836B3 (en)
HK (1) HK1041823A1 (en)
HU (1) HUP0202329A2 (en)
IL (1) IL145648A0 (en)
IS (1) IS6084A (en)
MX (1) MXPA01011071A (en)
NO (1) NO20015295L (en)
NZ (1) NZ514248A (en)
PL (1) PL351923A1 (en)
SK (1) SK15542001A3 (en)
TR (1) TR200103039T2 (en)
UY (1) UY26131A1 (en)
WO (1) WO2000066130A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1350511T3 (en) 2000-12-25 2009-01-05 Daiichi Sankyo Co Ltd Medicinal composition containing aspirin
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
JP4917255B2 (en) * 2003-10-16 2012-04-18 第一三共ヘルスケア株式会社 Oral composition containing salicylic acids
WO2005070464A2 (en) * 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
KR20070009851A (en) * 2005-07-14 2007-01-19 씨제이 주식회사 Pharmaceutical compositions containing clopidogrel bisulfate
WO2007035028A1 (en) * 2005-09-21 2007-03-29 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
KR20070044323A (en) * 2005-10-24 2007-04-27 에스케이케미칼주식회사 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
US20100145053A1 (en) * 2006-04-05 2010-06-10 Cadila Healthcare Limited Modified release clopidogrel formulation
EP1900358A1 (en) * 2006-09-16 2008-03-19 Cimex Pharma AG Pharmaceutical formulations comprising clopidogrel
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
JP2011512406A (en) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド Compound preparation
CN101695496A (en) * 2009-10-15 2010-04-21 苏春华 Medicinal composition containing triflusal and clopidogrel
JP2013032289A (en) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd Wax stable formulation
RU2484820C2 (en) * 2011-02-24 2013-06-20 Общество с ограниченной ответственностью "Озон" Combined medicine as thrombocyte aggregation inhibitor
KR101675501B1 (en) 2011-11-02 2016-11-14 한국유나이티드제약 주식회사 Combination of Clopidogrel and Aspirin
CN102406938A (en) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 Medicine composition for resisting thrombosis
JP6004524B2 (en) * 2012-07-11 2016-10-12 大原薬品工業株式会社 Method for producing clopidogrel sulfate-containing tablets
WO2015015062A1 (en) * 2013-08-02 2015-02-05 Sanofi Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel
CN104434932B (en) * 2014-12-18 2017-05-24 成都苑东生物制药股份有限公司 Pharmaceutical composition of clopidogrel hydrogen sulfate and acetylsalicylic acid tablet and preparation method thereof
WO2017037741A1 (en) * 2015-09-02 2017-03-09 Sun Pharmaceutical Industries Ltd Compact solid dosage form of aspirin and clopidogrel
CN115737578A (en) * 2022-11-23 2023-03-07 石家庄四药有限公司 Clopidogrel hydrogen sulfate and aspirin compound tablet and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2744918B1 (en) 1996-02-19 1998-05-07 Sanofi Sa NEW COMBINATIONS OF ACTIVE INGREDIENTS CONTAINING THIENO (3,2-C) PYRIDINE DERIVATIVE AND AN ANTITHROMBOTIC
FR2779726B1 (en) 1998-06-15 2001-05-18 Sanofi Sa POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE

Also Published As

Publication number Publication date
TR200103039T2 (en) 2002-01-21
JP2002543137A (en) 2002-12-17
NO20015295D0 (en) 2001-10-29
PL351923A1 (en) 2003-06-30
KR20020005735A (en) 2002-01-17
IS6084A (en) 2001-09-25
CZ20013887A3 (en) 2002-02-13
MXPA01011071A (en) 2002-07-22
SK15542001A3 (en) 2002-02-05
EP1178809A1 (en) 2002-02-13
AR023789A1 (en) 2002-09-04
AU4303600A (en) 2000-11-17
HUP0202329A2 (en) 2002-10-28
CN1359294A (en) 2002-07-17
BR0010194A (en) 2002-02-13
FR2792836B3 (en) 2001-07-27
NO20015295L (en) 2001-12-21
CA2371231A1 (en) 2000-11-09
EA200100959A1 (en) 2002-06-27
HK1041823A1 (en) 2002-07-26
EE200100559A (en) 2003-02-17
IL145648A0 (en) 2002-06-30
WO2000066130A1 (en) 2000-11-09
FR2792836A1 (en) 2000-11-03
NZ514248A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
UY26131A1 (en) PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID.
ES2176684T3 (en) NEW ASSOCIATIONS OF ACTIVE PRINCIPLES CONTAINING CLOPIDOGREL AND AN ANTHROMBOTIC.
DK1296670T3 (en) Therapeutic fatty acid combinations
BR0109925A (en) Taste Masking Coating Composition
DE69901570T2 (en) RANOLAZINE-CONTAINING MEDICINES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
EE200000595A (en) Delivery of the active ingredient to the carrier matrix
EP1419785A4 (en) Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
AR028327A1 (en) TRANSDERMAL OR TRANSMUCOSAL PRESENTATION FORMS CONTAINING A COMBINATION OF ACTIVE PRINCIPLES INTENDED FOR THE DISHABITATION OF SMOKERS
DE69937891D1 (en) FLUVASTATIN MEDICINAL PRODUCT WITH DELAYED ACTIVE INGREDIENTS
ATE356622T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A LIPASE INHIBITOR AND A SUCROSE FATTY ACID MONOESTER
ES2143481T3 (en) SLOW RELEASE SODIUM VALPROATE TABLET.
IS6654A (en) Stable gabapentin with pH within the controlled range
BRPI0412697A (en) pharmaceutical compositions having an expandable coating
WO2001070214A3 (en) The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy
MA31678B1 (en) Therapeutic clay composition
ATE291421T1 (en) PHARMACEUTICAL EFFORTABLE FORMULATION CONTAINING RAMIPRIL
AR030648A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED EXCIPIENT
NO20014081D0 (en) Use of tianeptin in the manufacture of drugs to treat neurodegenerative pathologies
DE60110814D1 (en) COMPOSITIONS WITH SLOW RELEASE CONTAINING LITHIUM CARBONATE
IT1297233B1 (en) SOLID PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CANDIES CONTAINING DISINFECTANTS AND MUCO-ADHESIVE SUBSTANCES FOR TOPICAL DISINFECTION
ATE258046T1 (en) PHARMACEUTICAL EFFORTABLE FORMULATION CONTAINING METAMIZOLE
ATE302261T1 (en) STABILIZED TRANSPARENT SOAP COMPOSITION
WO2001066115A3 (en) Acetylsalicylic acid solutions
ATA171599A (en) PHARMACEUTICAL COMPOSITION TO MEET THE BASIC NEEDS OF VITAMINS
NL1015043A1 (en) Use of N-anisole-gamma-aminobutyric acid or p-methoxybenzoic acid in medicines.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100804